Artiva Biotherapeutics, a Phase 1 biotech developing off-the-shelf natural killer cell-based therapies for autoimmune diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The company had previously filed for an IPO in 2021, but ultimately withdrew the offering in late 2022. It never set terms.
Artiva is focused on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its candidates are derived from donor cells (allogeneic) rather than a patient's own cells (autologous) and are pre-manufactured, stored frozen, and ready to ship, making them what it believes to be "off-the-shelf." Its lead candidate, AlloNK, is currently in an ongoing Phase 1/1b trial in lupus nephritis and a basket investigator-initiated trial in multiple autoimmune indications. Artiva expects to report initial data from at least one of these trials in the 1H25.
The San Diego, CA-based company was founded in 2019 and booked $33 million in collaboration and license revenue for the 12 months ended March 31, 2024. It plans to list on the Nasdaq under the symbol ARTV. Artiva Biotherapeutics filed confidentially on May 3, 2024. Jefferies, TD Cowen, and Cantor Fitzgerald are the joint bookrunners on the deal. No pricing terms were disclosed.
